Hepatitis SA, 6 September 2016 A clinical trial is now open for people who have been diagnosed with chronic Hepatitis B Virus (HBV) infection, who have not had treatment for this condition in the last 2 years. Other entry requirements apply. The purpose of this research study is to assess the effectiveness and safety of a novel medicine for the treatment of patients with chronic Hepatitis B...
AFAO publishes Australian PrEP roundup
Australian Federation of AIDS Organisations (AFAO), 23 August, 2016 Following the Pharmaceutical Benefits Advisory Committee (PBAC) decision not to recommend funding PrEP through the Pharmaceutical Benifits Scheme (PBS), AFAO has produced an Australian PrEP roundup paper to sustain advocacy efforts and to raise awareness about current options for accessing PrEP around the country. In releasing...
HIV prevention drug PrEP being tested on high-risk adolescents
Sydney Morning Herald, July 21 2016
A preventative HIV drug being used by thousands of gay men in Australia is being tested on teenagers at high risk of the virus.
Studies have shown that PrEP (pre-exposure prophylaxis) offers near complete protection against HIV if taken properly every day. Researchers are now testing it on young people in South Africa and the US.
Read more here
PrEP: HIV drug trials expanding to 2,000 men in Qld after ‘brave’ government decision
ABC News, 27/04/16, 5:12pm
A groundbreaking new drug tipped to stop the spread of HIV within just a few years will be available to more than 2,000 Queensland men under a $6 million trial program.
The trials make Pre-Exposure Prophylaxis (PrEP) available to men who have sex with men, as a means of preventing HIV transmission.
Read more here
Vaginal ring cuts HIV risk by nearly one-third: studies
Yahoo news, February 23, 2016 2:05 AM
A monthly vaginal ring that contains an anti-retroviral drug has been shown to cut the risk of HIV infection in women by nearly one-third, according to two international studies.
Read more here
Women under-represented in HIV clinical trials
nam/aidsmap, 08 February 2016
Less than a quarter of people taking part in clinical trials for antiretroviral medications are women, potentially limiting the generalisability of findings, according to a systematic review published in the February 1 edition of the Journal of Acquired Immune Deficiency Syndromes.
Read more here